[Nika]

Sanguine Convenes Its Medical Advisory Board

Business Wire; 3/7/2005

PASADENA, Calif. -- Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced that it is convening its Medical Advisory Board in California early next month to discuss the final selection of a contract research organization to initiate and run its animal testing, and the selection of PHER-O2 manufacturer.
The Medical Advisory Board is comprised of industry professionals whose experience and influence significantly aid Sanguine in furthering its mission to provide the world with a truly successful synthetic blood. The company has been recently asked by many shareholders as to the current status of its medical board. Sanguine's Medical Advisory Board and medical advisors include the following:

Thomas C. Drees, Ph.D. -- founder, president and CEO; board chairman

Drees founded Sanguine Corp., having worked at the forefront of the blood substitute business for more than 30 years. Drees was the president and CEO of Alpha Therapeutics, the only company to obtain FDA approval for a blood substitute product for human use. He has many years of experience with FDA approval, and the development, marketing and management of artificial blood products. Drees is one of the most experienced individuals in the field of blood substitutes. He has published many articles and a book on the subject of blood substitutes, and has consulted worldwide for the blood industry through Drees International Inc. He was an officer and director of the American Blood Resources Association and American Blood Commission.

Drees' role in the company is to drive the business technical and regulatory development of PHER-O2. He also holds four patent applications and two approved patents on fluorocarbon synthetic red blood cells.

Robert Kwun, M.D. -- Kwun received his undergraduate degree from Harvard University and his doctor of medicine degree from Columbia University in New York. Kwun's clinical training includes Columbia University's Manhattan Eye, Ear and Throat Hospital; Los Angeles Children's -- USC Medical Center; the Doheny Eye Institute; and New York's St. Vincent's Hospital. Kwun has received numerous honors and awards in retinal surgery in addition to having authored or co-authored many articles in the area of macular degeneration and other areas of ophthalmic surgery.

L. Cass Terry, M.D., Ph.D., Pharm.D. -- Terry currently serves in a number of important academic and clinical appointments. Terry was most recently the chairman of the department of neurology, Medical College of Wisconsin; chief of staff, Froedtert Memorial Lutheran Hospital; professor of neurology, Medical College of Wisconsin; and professor of physiology, Medical College of Wisconsin.

Terry has a critical array of contacts in both the medical and academic communities, which will greatly enhance the development of Sanguine's technology. Sanguine will utilize his strong clinical background in anti-aging research to promote PHER-O2's development.

Terry has lead an extensive number of studies, funded by more than $6.9 million in research grants over the past 20 years. These studies have lead to authorship or co-authorship of well over 100 publications.

Craig Morrison, M.D. -- Morrison is currently an attending staff general surgeon at the following hospitals: Utah Valley Regional Medical Center, Orem Community Hospital, Colombia Timpanogos Regional Hospital, Colombia Mountain View Hospital and Brigham Young University Student Health Center. Morrison is a member of several medical advisory boards specializing on novel surgical approaches.

Herbert J. Meiselman, Sc.D. -- Meiselman, an expert in rheology, which is the science of the flow of blood through the heart and blood vessels, is currently a professor of physiology and biophysics at the University of Southern California School of Medicine, Los Angeles.

Medical Adviser:

Joseph P. O'Malley, M.D. -- O'Malley is a graduate cum laude of Harvard Medical School. He was a member of the National Institute of Health's biologics (science of blood therapy) department for 10 years, and moved with the division to the Food and Drug Administration (FDA) when it was transferred. He remained with the FDA for seven years, after which he worked with the American Red Cross for 15 years. He also served with the Public Health Services for many years.

His knowledge of the field of biologics is extensive, as are his contacts in the various organizations studying blood and its management today. O'Malley will help shepherd Sanguine through the FDA clinical trial process required to bring PHER-O2 to market.

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors and hemorrhagic shock. The company is also developing non-medical applications for its perfluorocarbon (PFC) product.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.